Clinical Trial: A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis

U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07312604) titled 'A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis' on Dec. 17, 2025.

Brief Summary: This pilot study will test intra-lesional immunotherapy (MMR vaccine) injections as a treatment for recalcitrant tinea cruris and corporis in patients aged 10-60 years who have not improved with standard antifungal treatments.

*Eligibility: Participants must have recalcitrant tinea, defined as:

* Rapid progression or large areas of skin affected,

* Infection in multiple family members, especially females and children

* Rapid relapse after prio...